Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women

Contraception

Volumn 79, Issue 1, 2009, Pages 35-40

  Lizarelli, Patrícia Margareth ^a   Martins, Wellington Paula ^a   Vieira, Carolina Sales ^a   Soares, Gustavo Mafaldo ^a   Franceschini, Sílvio Antônio ^a   Ferriani, Rui Alberto ^a   Patta, Maristela Carbol ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial function; Cardiovascular disease; Combined oral contraceptives; Echographic cardiovascular markers; Endothelial functional; Progestogen only contraceptives

Indexed keywords

CHOLESTEROL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL;

ADULT; ARTERIAL PRESSURE; ARTERY BLOOD FLOW; ARTERY COMPLIANCE; ARTERY DILATATION; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BODY MASS; BRACHIAL ARTERY; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HEART RATE; HORMONAL CONTRACEPTION; HUMAN; INTRAVASCULAR ULTRASOUND; NORMAL HUMAN; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; REGIONAL BLOOD FLOW; RISK FACTORS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 56549126627     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.07.024     Document Type: Article

References (47)

1. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998;877:i-vii, 1-89.
2. Burkman R.T., Collins J.A., Shulman L.P., and Williams J.K. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185 (2001) S4-S12
3. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22 (2002) 201-210
4. Kemmeren J.M., Tanis B.C., van den Bosch M.A., et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 33 (2002) 1202-1208
5. Khader Y.S., Rice J., John L., and Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 68 (2003) 11-17
6. Baillargeon J.P., McClish D.K., Essah P.A., and Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 (2005) 3863-3870
7. Rosendaal F.R., Van Hylckama Vlieg A., Tanis B.C., and Helmerhorst F.M. Estrogens, progestogens and thrombosis. J Thromb Haemost 1 (2003) 1371-1380
8. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 346 (1995) 1575-1582
9. O'Rourke M.F., and Safar M.E. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 46 (2005) 200-204
10. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
11. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
12. Bots M.L., Hoes A.W., Hofman A., Witteman J.C., and Grobbee D.E. Cross-sectionally assessed carotid intima-media thickness relates to long-term risk of stroke, coronary heart disease and death as estimated by available risk functions. J Intern Med 245 (1999) 269-276
13. Boutouyrie P., Bussy C., Lacolley P., Girerd X., Laloux B., and Laurent S. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 100 (1999) 1387-1393
14. Heitzer T., Schlinzig T., Krohn K., Meinertz T., and Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
15. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
16. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes Jr. D.R., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
17. Weber T., Auer J., O'Rourke M.F., et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 109 (2004) 184-189
18. Abdu T.A., Elhadd T., Pfeifer M., and Clayton R.N. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 12 (2001) 257-265
19. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
20. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. (2004), World Health Organization, Geneva
21. Winkler U.H., Howie H., Buhler K., Korver T., Geurts T.B., and Coelingh Bennink H.J. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel. Contraception 57 (1998) 385-392
22. Vieira C.S., Ferriani R.A., Garcia A.A., et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 22 (2007) 2196-2201
23. Raitakari O.T., Juonala M., Kahonen M., et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 290 (2003) 2277-2283
24. Tsivgoulis G., Vemmos K., Papamichael C., et al. Common carotid arterial stiffness and the risk of ischaemic stroke. Eur J Neurol 13 (2006) 475-481
25. Mackenzie I.S., Wilkinson I.B., and Cockcroft J.R. Assessment of arterial stiffness in clinical practice. QJM 95 (2002) 67-74
26. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
27. Mather K.J., Verma S., Corenblum B., and Anderson T.J. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 85 (2000) 1851-1856
28. Sorensen M.B., Collins P., Ong P.J., et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 106 (2002) 1646-1651
29. Meirik O., Farley T.M., and Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynecol 97 (2001) 539-547
30. Mishell Jr. D.R. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41 (1996) 381-390
31. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340 (1999) 1801-1811
32. Collins P., and Webb C. Estrogen hits the surface. Nat Med 5 (1999) 1130-1131
33. Wellman G.C., Bonev A.D., Nelson M.T., and Brayden J.E. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels. Circ Res 79 (1996) 1024-1030
34. Darkow D.J., Lu L., and White R.E. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol 272 (1997) H2765-H2773
35. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 343 (1994) 1199-1206
36. Torgrimson B.N., Meendering J.R., Kaplan P.F., and Minson C.T. Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol. Am J Physiol Heart Circ Physiol 292 (2007) H2874-H2880
37. Rickenlund A., Eriksson M.J., Schenck-Gustafsson K., and Hirschberg A.L. Oral contraceptives improve endothelial function in amenorrheic athletes. J Clin Endocrinol Metab 90 (2005) 3162-3167
38. 2+ mobilization. Circ Res 81 (1997) 885-892
39. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46 Suppl 1 (2003) S7-S16
40. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
41. Enk L., Landgren B.M., Lindberg U.B., Silfverstolpe G., and Crona N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 24 (1992) 85-89
42. Graff-Iversen S., and Tonstad S. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian survey. Contraception 66 (2002) 7-13
43. Oyelola O.O. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Contraception 47 (1993) 445-454
44. Diab K.M., and Zaki M.M. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 26 (2000) 17-26
45. Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 65 (2002) 215-221
46. Skouby S.O., Endrikat J., Dusterberg B., et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception 71 (2005) 111-117
47. Faulx M.D., Wright A.T., and Hoit B.D. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 145 (2003) 943-951